全球脓毒症诊断市场规模、份额、趋势和成长分析报告（2026-2034年）

预计败血症诊断市场将从 2025 年的 7.9 亿美元成长到 2034 年的 15.6 亿美元，2026 年至 2034 年的复合年增长率为 7.89%。

由于医院感染率上升以及对这种危及生命的疾病早期检测需求的日益增长，全球脓毒症诊断市场正在扩张。快速诊断败血症对于预防器官衰竭和死亡至关重要。医护人员意识提升和诊断技术的进步正在推动市场需求。生物标记、分子诊断和自动化血液培养系统的应用提高了败血症检测的速度和准确性。

人口老化、慢性病病例增加以及全球住院人数上升是推动市场成长要素。政府为降低败血症相关死亡率和改善重症监护管理所采取的措施也进一步促进了市场成长。就地检验和人工智慧诊断工具等技术进步提高了效率。医院和诊断检查室正在投资先进系统，旨在缩短检测结果等待时间并改善患者预后。

展望未来，在数位健康解决方案和即时监测系统整合的推动下，市场预计将实现强劲成长。尤其是在急诊医疗环境中，快速诊断试剂盒和携带式检测设备的应用将显着增加。在新兴市场，随着健康意识的不断提高，先进技术的应用预计将会更加普及。持续的技术创新和早期诊断解决方案的普及将进一步增强败血症诊断市场的未来前景。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球脓毒症诊断市场：依产品划分

• 市场分析、洞察与预测
• 血液培养基
• 装置
• 检测试剂盒和试剂
• 软体

第五章：全球脓毒症诊断市场：依技术划分

• 市场分析、洞察与预测
• 微生物学
• 分子诊断
• 免疫检测
• 流式细胞技术

第六章：全球败血症诊断市场：依方法类型划分

• 市场分析、洞察与预测
• 传统诊断方法
• 自动化诊断

第七章 全球败血症诊断市场：依病原体类型划分

• 市场分析、洞察与预测
• 细菌性败血症
• 霉菌性败血症
• 其他的

第八章：全球脓毒症诊断市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 诊断中心
• 诊所
• 其他的

第九章 全球脓毒症诊断市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott Laboratories
  • BioMAfA（C）Rieux SA
  • Thermo Fisher Scientific Inc
  • Becton
  • Dickinson And Company
  • Bruker Corporation
  • Beckman Coulter Inc
  • T2 Biosystems Inc
  • Nanosphere Inc
  • Hoffmann-La Roche Ltd
  • Danaher Corporation

The Sepsis Diagnostics Market size is expected to reach USD 1.56 Billion in 2034 from USD 0.79 Billion (2025) growing at a CAGR of 7.89% during 2026-2034.

The Global Sepsis Diagnostics Market is expanding due to the rising incidence of hospital-acquired infections and the growing need for early detection of life-threatening conditions. Sepsis requires rapid diagnosis to prevent organ failure and mortality. Increasing awareness among healthcare providers and advancements in diagnostic technologies are driving demand. The use of biomarkers, molecular diagnostics, and automated blood culture systems has improved the speed and accuracy of sepsis detection.

Key growth drivers include the increasing geriatric population, rising cases of chronic diseases, and growing hospital admissions worldwide. Government initiatives to reduce sepsis-related deaths and improve critical care management are further supporting market growth. Technological developments such as point-of-care testing and AI-based diagnostic tools are enhancing efficiency. Hospitals and diagnostic laboratories are investing in advanced systems to reduce turnaround time and improve patient outcomes.

Looking ahead, the market is expected to witness strong growth with the integration of digital health solutions and real-time monitoring systems. Rapid diagnostic kits and portable testing devices will likely gain popularity, especially in emergency settings. Emerging markets are projected to adopt advanced technologies as healthcare awareness rises. Continuous innovation and improved access to early diagnostic solutions will strengthen the future prospects of the Sepsis Diagnostics Market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Blood Culture Media
• Instruments
• Assay Kits & Reagents
• Software

By Technology

• Microbiology
• Molecular Diagnostics
• Immunoassays
• Flow Cytometry

By Method Type

• Conventional Diagnostics
• Automated Diagnostics

By Pathogen Type

• Bacterial Sepsis
• Fungal Sepsis
• Others

By End-use

• Hospitals
• Diagnostic Centres
• Clinics
• Others

COMPANIES PROFILED

• Abbott Laboratories, BioMrieux SA, Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter Inc, T2 Biosystems Inc, Nanosphere Inc, HoffmannLa Roche Ltd, Danaher Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SEPSIS DIAGNOSTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Blood Culture Media Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Assay Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Microbiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunoassays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Flow Cytometry Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SEPSIS DIAGNOSTICS MARKET: BY METHOD TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Method Type
• 6.2. Conventional Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Automated Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SEPSIS DIAGNOSTICS MARKET: BY PATHOGEN TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Pathogen Type
• 7.2. Bacterial Sepsis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Fungal Sepsis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SEPSIS DIAGNOSTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End-use
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Diagnostic Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL SEPSIS DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product
  • 9.2.2 By Technology
  • 9.2.3 By Method Type
  • 9.2.4 By Pathogen Type
  • 9.2.5 By End-use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product
  • 9.3.2 By Technology
  • 9.3.3 By Method Type
  • 9.3.4 By Pathogen Type
  • 9.3.5 By End-use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product
  • 9.4.2 By Technology
  • 9.4.3 By Method Type
  • 9.4.4 By Pathogen Type
  • 9.4.5 By End-use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product
  • 9.5.2 By Technology
  • 9.5.3 By Method Type
  • 9.5.4 By Pathogen Type
  • 9.5.5 By End-use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product
  • 9.6.2 By Technology
  • 9.6.3 By Method Type
  • 9.6.4 By Pathogen Type
  • 9.6.5 By End-use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL SEPSIS DIAGNOSTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Abbott Laboratories
  • 11.2.2 BioMAfA(C)Rieux SA
  • 11.2.3 Thermo Fisher Scientific Inc
  • 11.2.4 Becton
  • 11.2.5 Dickinson And Company
  • 11.2.6 Bruker Corporation
  • 11.2.7 Beckman Coulter Inc
  • 11.2.8 T2 Biosystems Inc
  • 11.2.9 Nanosphere Inc
  • 11.2.10 Hoffmann-La Roche Ltd
  • 11.2.11 Danaher Corporation